Loading...
XSTO
ANNX
Market cap22mUSD
Jun 13, Last price  
30.10SEK
1D
-2.90%
1Q
9,306.25%
IPO
391.04%
Name

Annexin Pharmaceuticals AB (publ)

Chart & Performance

D1W1MN
XSTO:ANNX chart
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
55.61%
Rev. gr., 5y
%
Revenues
0k
Net income
-50m
L+14.07%
-1,386,963-5,029,000-9,830,000-30,927,000-28,847,000-28,394,000-44,743,000-53,051,000-40,726,000-44,054,000-50,252,000
CFO
-50m
L+15.72%
0-5,012,000-9,949,000-39,082,000-28,504,000-25,725,000-39,199,000-45,024,000-41,165,000-43,403,000-50,228,000

Profile

Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.
URL
https://www.annexinpharma.com/
IPO date
Apr 19, 2017
Employees
5
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
50,397
44,232
40,849
Unusual Expense (Income)
NOPBT
(50,397)
(44,232)
(40,849)
NOPBT Margin
Operating Taxes
(193)
Tax Rate
NOPAT
(50,397)
(44,232)
(40,656)
Net income
(50,252)
14.07%
(44,054)
8.17%
(40,726)
-23.23%
Dividends
Dividend yield
Proceeds from repurchase of equity
45,056
36,503
23,107
BB yield
-23.01%
-84.02%
-9.59%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
3,329
Net debt
(16,337)
(21,726)
(31,521)
Cash flow
Cash from operating activities
(50,228)
(43,403)
(41,165)
CAPEX
Cash from investing activities
96
(260)
Cash from financing activities
45,151
33,608
23,060
FCF
(50,307)
(44,142)
(40,566)
Balance
Cash
16,337
21,415
31,114
Long term investments
311
407
Excess cash
16,337
21,726
31,521
Stockholders' equity
(327,642)
(280,475)
(239,478)
Invested Capital
341,355
299,289
269,631
ROIC
ROCE
EV
Common stock shares outstanding
452,172
167,106
241,457
Price
0.43
66.54%
0.26
-73.95%
1.00
-0.20%
Market cap
195,790
350.64%
43,448
-81.97%
240,974
77.94%
EV
179,453
21,722
209,453
EBITDA
(50,397)
(44,039)
(40,656)
EV/EBITDA
Interest
2
Interest/NOPBT